Goserelin plus anastrozole for the treatment of premenopausal women with hormone receptor positive, recurrent/metastatic breast cancer

被引：0
|
作者：
Carlson, RW
Schurmann, CM
Rivera, E
Chung, CT
Phan, SC
Dice, EK
Arun, B
Thomas, E
Valero, V
机构：
[1] Stanford Univ, Stanford, CA 94305 USA
[2] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2004年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S237 / S238
页数：2
相关论文
共 50 条
  • [1] Goserelin plus anastrozole in the treatment of premenopausal hormone receptor positive, recurrent or metastatic breast cancer
    Carlson, R. W.
    Schurman, C. M.
    Rivera, E.
    Chung, C. T.
    Phan, S. C.
    Dice, E. K.
    Thomas, E.
    Valero, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Phase II Trial of Anastrozole Plus Goserelin in the Treatment of Hormone Receptor-Positive, Metastatic Carcinoma of the Breast in Premenopausal Women
    Carlson, Robert W.
    Theriault, Richard
    Schurman, Christine M.
    Rivera, Edgardo
    Chung, Cathie T.
    Phan, See-Chun
    Arun, Banu
    Dice, Kristine
    Chiv, Vivian Y.
    Green, Marjorie
    Valero, Vicente
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (25) : 3917 - 3921
  • [3] Anastrozole and goserelin combination as first treatment for premenopausal receptor positive advanced or metastatic breast cancer: A phase II trial
    Roche, H. H.
    Thierry, D.
    Chieze, S.
    Pierre, K.
    Veyret, C.
    Abadie, S.
    Campone, M.
    Florence, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Clinical efficacy of combined goserelin and anastrozole in neoadjuvant endocrine therapy for premenopausal women with hormone receptor-positive breast cancer
    Han, Xu
    Li, Hui
    Zhou, Shui-Ying
    Dong, Sha-Sha
    Zhang, Gang-Ling
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [5] Goserelin plus anastrozole as first-line endocrine therapy for premenopausal women with oestrogen receptor (ER) positive advanced breast cancer (ABC).
    Cheung, KL
    Winterbottom, L
    Owers, R
    Robertson, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 60S - 60S
  • [6] A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer
    Robert W. Carlson
    Anne O’Neill
    Tatiana Vidaurre
    Henry L. Gomez
    Sunil S. Badve
    George W. Sledge
    Breast Cancer Research and Treatment, 2012, 133 : 1049 - 1056
  • [7] A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer
    Carlson, Robert W.
    O'Neill, Anne
    Vidaurre, Tatiana
    Gomez, Henry L.
    Badve, Sunil S.
    Sledge, George W.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 133 (03) : 1049 - 1056
  • [8] Fulvestrant plus anastrozole as neoadjuvant therapy in postmenopausal women with hormone receptor positive early breast cancer
    Khan, Q. J.
    Barr, J. A.
    Britt, A. S.
    Kimler, B. F.
    Connor, C. S.
    McGinness, M.
    Mammen, J. M. V.
    Wagner, J. L.
    Amin, A.
    Springer, M.
    Baccaray, S.
    Fabian, C. J.
    Sing, A. P.
    Sharma, P.
    CANCER RESEARCH, 2016, 76
  • [9] MIRACLE study (CBCSG016): A randomized phase II study of letrozole versus letrozole plus everolimus for hormone receptor positive premenopausal women with recurrent or metastatic breast cancer on goserelin treatment after progession on tamoxifen.
    Xu, Binghe
    Liu, Donggeng
    Lu, Jinsong
    Ouyang, Tao
    Li, Xiang
    Fan, Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] LHRH agonists: treatment for hormone-receptor-positive breast cancer in premenopausal women
    Nature Clinical Practice Oncology, 2007, 4 (9): : 500 - 501
12345